Diplomat Pharmacy Considers Its Options

In conjunction with its second-quarter earnings, Diplomat Pharmacy (NYSE: DPLO) disclosed that it's undergoing a review of strategic alternatives that could result in selling all or part of the business. Considering that the second quarter didn't live up to expectations, that may end up as the best option for shareholders.

Metric

Q2 2019

Continue reading

Source Fool.com